The FDA's approval of Eve, the first self-balancing, personal exoskeleton, marks a significant milestone in the field of assistive technology. This innovative device is designed to enable eligible adult wheelchair users with spinal cord injury to walk and perform daily activities without the need for manual assistance.
Key Insights
Eve's approval is based on clinical trials that demonstrated improvements in users' health status, psychological well-being, and daily life activities. The device's self-balancing technology allows for greater stability and mobility, providing users with a greater sense of independence and confidence.










